Stem Cell Research and Cancer-causing Mutations: Potential and Challenges – Medriva

Stem cell research, hailed as the future of regenerative medicine, holds immense potential for treating a myriad of diseases. However, a recent study has revealed that approximately one-fifth of stem cells grown in laboratories for medical treatments possess cancer-causing mutations. Although these cells have not been injected into humans, they are being used in research to explore their potential for medical use.

Recent studies have shown a huge variation in mutations for induced pluripotent stem cells (iPSCs), some of which severely limit their transformative abilities. Aging and evolutionary pressures cause these cells to harbor more mutations than previously suspected. Interestingly, a significant percentage of stem cell lines contained BCOR mutations predicted to be pathogenic. These mutations impaired the stem cells abilities to differentiate into other tissues, with the mutational process mainly focused on BCOR during the stem cell reprogramming process.

Despite these challenges, scientists are not deterred from exploring the potential of stem cells in cancer therapies. In a groundbreaking study, scientists from UC San Francisco and Northwestern University introduced a mutation found in cancer cells into CAR-T cells, a type of immune cell modified in the lab to fight cancer. This mutation supercharged the CAR-T cells, making them 100 times more potent against cancer cells. This innovative therapy was able to destroy solid skin, lung, and stomach tumors in mice, setting the stage for further development in human trials.

Research has also focused on the activation of lineage-inappropriate signaling pathways by leukemic stem cells (LSCs) to promote their growth. These cells aberrantly activate the VEGF and IL-5 signaling pathways, which allows them to re-enter the cell cycle while preserving self-renewal capacity. Inhibitors for VEGFA and IL5RA have shown promise in reducing proliferation, indicating these pathways as potential targets for treatment.

Further illustrating the potential of stem cells, City of Hope has reported a successful case of treating the oldest patient to achieve remission from leukemia and HIV. The patient received a blood stem cell transplant from a donor with a rare genetic mutation and was given reduced-intensity chemotherapy before the transplant. This case demonstrates the potential of stem cell transplantation in achieving remission from HIV and cancer, even in older patients.

While the presence of cancer-causing mutations in laboratory-grown stem cells poses a significant challenge, the potential breakthroughs in medical treatments such cells provide cannot be ignored. The future of regenerative medicine hinges on the successful management of these mutations and the harnessing of stem cells transformative abilities. Continued research and development in this field are essential to fully unlock the potential of stem cells for the benefit of medical science and patient care.

Read more here:
Stem Cell Research and Cancer-causing Mutations: Potential and Challenges - Medriva

Achieving Joint Health: Europe’s Leading Stem Cell Solutions for Osteoarthritis – Medical Tourism Magazine

Osteoarthritis (OA) affects millions worldwide, causing pain, stiffness, and reduced mobility in joints. Traditional treatments often involve medication, physical therapy, or even joint replacement surgery. However, advancements in regenerative medicine have led to innovative solutions, particularly in Europe, offering hope for those seeking effective, non-invasive alternatives. In this article, we explore Europe's leading stem cell solutions for osteoarthritis, highlighting the cutting-edge therapies and top clinics pioneering these treatments.

Osteoarthritis is a degenerative joint disease characterized by the breakdown of cartilage, leading to pain, inflammation, and impaired joint function. Commonly affecting weight-bearing joints such as the knees, hips, and spine, OA significantly impacts quality of life for affected individuals. Traditional treatments focus on managing symptoms and slowing disease progression, but they often fail to address the underlying cause or provide long-term relief.

Stem cell therapy holds immense promise in the field of regenerative medicine, offering the potential to repair damaged tissues and promote healing within the body. In the context of osteoarthritis, stem cell treatments aim to regenerate cartilage, reduce inflammation, and improve joint function without the need for invasive surgeries. This innovative approach has garnered attention for its ability to provide long-lasting relief and potentially halt the progression of OA.

Europe has emerged as a hub for cutting-edge stem cell research and therapies, attracting patients from around the globe seeking advanced medical treatments. Several European clinics and medical centers specialize in offering stem cell solutions for osteoarthritis, utilizing state-of-the-art technologies and pioneering approaches to patient care. These facilities adhere to strict regulatory standards and prioritize patient safety and satisfaction, making them highly sought-after destinations for medical tourists seeking effective joint treatments.

European clinics offering stem cell therapies for osteoarthritis employ various techniques to deliver optimal results for patients. From adipose-derived stem cell injections to bone marrow aspiration procedures, these treatments harness the regenerative potential of stem cells to repair damaged cartilage and alleviate joint pain. Additionally, some clinics utilize platelet-rich plasma (PRP) therapy in conjunction with stem cell treatments to enhance healing and accelerate recovery.

When considering stem cell therapy for osteoarthritis, it's essential to research and select a reputable clinic with a proven track record of success. Patients should look for facilities staffed by experienced medical professionals who specialize in regenerative medicine and orthopedics. Furthermore, clinics should prioritize patient education and provide comprehensive consultations to ensure individuals fully understand the treatment process, potential risks, and expected outcomes.

Europe's leading stem cell solutions for osteoarthritis offer new hope for individuals suffering from joint pain and mobility issues. With cutting-edge therapies and state-of-the-art facilities, patients can access innovative treatments that provide effective relief without the need for invasive surgeries. As regenerative medicine continues to advance, the future looks promising for those seeking to achieve optimal joint health and improve their overall quality of life.

To conclude, In the quest for joint health, Europe stands at the forefront of innovation, offering advanced stem cell solutions that redefine the treatment landscape for osteoarthritis. Through ongoing research, technological advancements, and a commitment to excellence in patient care, European clinics continue to pave the way for a brighter, more pain-free future for individuals living with osteoarthritis.

Given his unparalleled expertise and success in treating elite athletes and high-profile individuals, we highly recommend Dr. Chad Prodromos for anyone seeking top-tier stem cell treatment. His work at the Prodromos Stem Cell Institute is at the forefront of regenerative medicine, offering innovative solutions for a range of conditions. To explore how Dr. Prodromos can assist in your health journey, consider reaching out through his clinic's website for more detailed information and to schedule a consultation. visit Prodromos Stem Cell Institute.

Disclaimer: The content provided in Medical Tourism Magazine (MedicalTourism.com) is for informational purposes only and should not be considered as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. We do not endorse or recommend any specific healthcare providers, facilities, treatments, or procedures mentioned in our articles. The views and opinions expressed by authors, contributors, or advertisers within the magazine are their own and do not necessarily reflect the views of our company. While we strive to provide accurate and up-to-date information, We make no representations or warranties of any kind, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained in Medical Tourism Magazine (MedicalTourism.com) or the linked websites. Any reliance you place on such information is strictly at your own risk. We strongly advise readers to conduct their own research and consult with healthcare professionals before making any decisions related to medical tourism, healthcare providers, or medical procedures.

Continued here:
Achieving Joint Health: Europe's Leading Stem Cell Solutions for Osteoarthritis - Medical Tourism Magazine

Drug used for cocaine addiction may pave way for new treatment of advanced colon cancer – EurekAlert

image:

This new research published in Nature Cancer led by Dr. Yannick Benoit, Principal Investigator and Associate Professor in the Department of Cellular and Molecular Medicine (Faculty of Medicine) at uOttawa, has revealed that vanoxerine plays an entirely unexpected mechanism in cancer.

Credit: University of Ottawa

A new, cutting-edge study from the University of Ottawa (uOttawa) has found vanoxerine, a drug initially developed for the treatment of cocaine addiction, could impede advanced colorectal cancer stem cells by essentially re-wiring critical gene networks.

This new research published in Nature Cancer led by Dr. Yannick Benoit, Principal Investigator and Associate Professor in the Department of Cellular and Molecular Medicine (Faculty of Medicine) at uOttawa, has revealed that vanoxerine plays an entirely unexpected mechanism in cancer. The investigators observed that vanoxerine packs a powerful punch when suppressing cancer stem cell activity in colon cancer patients tissues and in tumours implanted in laboratory animals. It interferes with a protein that transports dopamine, the brain chemical involved in sensations of pleasure and reward, and represses an enzyme dubbed G9a in colorectal tumours.

Notably, the tumours treated with vanoxerine become more susceptible to attack by the immune system due to the reactivation of ancient viral DNA fragments accumulated in our genome throughout evolution. This finding is quite significant, considering that colorectal tumours tend to show poor response to standard immunotherapy, says Dr. Benoit, who was one of six national winners of the Gairdner Foundations 2022 Early Career Investigator competition.

A silent killer

Colorectal cancer - when cells grow and divide uncontrollably in the colon or rectum - is the worlds second leading cause of cancer-related deaths and is considered a silent cancer since it typically doesnt cause symptoms during early stages. While the risks increase with age, new statistics show an alarming increase among younger adults.

Because its frequently diagnosed at advanced stages when treatment options are few, it is imperative to discover new methods of beating back colorectal cancer cells and tumours. When seeking a drug safely tested in patients, the most promising option turned out to be vanoxerine, a dopamine reuptakeinhibitor.

The research team observed such minimal toxicity from vanoxerine treatments when testing in healthy human and mouse tissues that Dr. Benoit says their work potentially floats a safe way to eliminate cancer stem cells in colorectal tumours without harming the good stem cells in the body's organs.

New and promising treatment

While prevention and early detection remain the best weapons against colorectal cancer, these highly compelling findings may pave the way for a new and promising treatment option for patients struggling with advanced disease.

For those unfortunate people diagnosed with advanced and aggressive forms of colorectal cancer, we profoundly hope our work can lead to the development of powerful options for treatment in the future and substantially increase their survival chances, says Dr. Benoit.

Roots of collaboration

The study was strongly collaborative, benefitting from expertise across the uOttawa Faculty of Medicines broad research ecosystem.

The first author is Christopher Bergin, a recent PhD graduate from Dr. Benoits lab who methodically tested vanoxerine for its anti-cancer stem cell properties in patient-derived organoids. Dr. Rebecca Auer, scientific director of The Ottawa Hospitals Cancer Therapeutics Program, provided access to colorectal cancer patients tissues. Dr. Mario Tiberi and Dr. Michele Ardolino provided critical insights and expertise.

While working on this study, Dr. Benoits lab hosted Dr. Tanguy Fenouil, a gastrointestinal pathologist from France whose collaborative work was key.

Meta-analysis

Cells

The dopamine transporter antagonist vanoxerine inhibits G9a and suppresses cancer stem cell functions in colon tumors

13-Feb-2024

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Link:
Drug used for cocaine addiction may pave way for new treatment of advanced colon cancer - EurekAlert

Chinese team tests lung treatment that may be first to reverse COPD damage – South China Morning Post

But through preclinical studies in mice and monkeys, the team and other scientists have found that resident progenitor lung cells capable of differentiating into multiple types of lung cells had a capacity for regeneration.

Healthy progenitor cells are often deficient in patients with COPD, however even those with the most severe stages of the disease still have healthy cells that can be isolated and used in personalised treatments.

These cells could be used as a Band-Aid for the lungs which could repair tissues in the airways and even deeper into the alveoli, the paper said.

Stem cell and progenitor cell-based regenerative medicine may be the biggest, if not the only, hope to cure COPD, Zuo Wei, study author and a professor at the Tongji University School of Medicine, said during a presentation at the European Respiratory Society International Congress last year.

In a phase 1 clinical trial of their treatment, the team collected healthy progenitor lung cells, called P63+, from the patients lungs via a bronchoscopy. The cells were then cultured in a lab for three to five weeks to make millions of cell clones.

Once the cells had multiplied, they were transplanted back into the patients via another bronchoscopy. A final evaluation of the patients was conducted six months after treatment.

The 17 patients with varying stages of COPD who received the treatment had no serious adverse side effects, and those that did occur were primarily a result of the bronchoscopy procedure, the team wrote.

New Chinese drug shows record treatment success against deadly lung cancer type

The scientists also did not observe any signs of tumour formation in the patients six months after transplant.

When evaluating the lungs ability to diffuse carbon monoxide which is used as a lung function test for COPD the scientists found that the study group had improved diffusion capacity compared to the baseline and control patients.

During a six-minute walking test, the study group was able to walk around 30 metres further after the treatment, which was a clinically meaningful improvement in exercise capacity, the paper said.

Surveys of the trial participants also suggested that most patients in the intervention group had an improved quality of life after treatment, the team wrote.

03:05

Heavy smog descends on India, leaving residents struggling to breathe

Heavy smog descends on India, leaving residents struggling to breathe

We found that P63+ progenitor cell transplantation not only improved the lung function of patients with COPD, but also relieved their symptoms, such as shortness of breath, loss of exercise ability and persistent coughing, Zuo said.

The improvement in gas diffusion capacity and walking distance in the treated patients supports further clinical studies of P63+ progenitor cells for the treatment of COPD Melissa Norton, senior editor of the journal, said in an editors summary of the paper.

Their symptoms will become worse: climate change threat to lung patients

The authors said the first phase of the clinical trial proved their treatment was safe and well tolerated, but it was limited to a small sample size comprising only men, so it was not suitable to determine efficacy yet.

To address this, the team is conducting an ongoing phase 2 clinical trial with a larger study group and follow-up time that looks at more indicators of lung function.

Go here to read the rest:
Chinese team tests lung treatment that may be first to reverse COPD damage - South China Morning Post

Stopping the awakening of sleeping Acute Myeloid Leukaemia stem cells to prevent disease relapse – University of Birmingham

New study provides clues to why leukaemic stem cells not harmed by chemotherapy begin to grow and produce AML cells after treatment.

Published 15 February 2024

The mystery of why myeloid leukaemias start to grow again after chemotherapy has killed the bulk of malignant cells, and how growth may be blocked by repurposed drugs, has potentially been solved through new research.

The bone marrow of AML patients contains a rare population of leukaemic stem cells (LSCs) that do not grow and therefore are not killed by chemotherapy. However, after treatment, these cells start to grow and produce AML cells, but it was unclear what kick-starts this process.

In a new study published in Nature Communications, researchers from the University of Birmingham, Newcastle University and the Princess Maxima Centre of Pediatric oncology studied single cells from patients with t(8;21) Acute Myeloid Leukaemia, a specific type of blood cancer, to investigate what made the rare LSCs grow.

Leukaemic stem cells normally seem asleep which is why they are not killed by chemotherapy, but we reasoned that something must trigger them to start growing in order for the leukaemia to come back.

Professor Constanze Bonifer from the Institute of Cancer and Genomic Sciences at the University of Birmingham who led the study said:

"Leukaemic stem cells normally seem asleep which is why they are not killed by chemotherapy, but we reasoned that something must trigger them to start growing in order for the leukaemia to come back.

These cells are very rare and difficult to study but by examining gene expression in single LSCs we found genes being expressed that encode for growth regulators normally not present in myeloid cells. Both cell types are found in the bone marrow alongside the AML cells, but healthy stem cells do not respond to their signals. By aberrantly upregulating these growth regulators, leukaemic stem cells now can respond to growth factors that are present in the body and tell them to grow."

The growth regulators, identified in this study were KDR, the receptor for VEGF signalling which is normally only expressed in blood vessels and the IL-5 receptor which is normally only expressed on eosinophils. Moreover, VEGFA, the growth factor binding to KDR, was also expressed by the leukaemia meaning it could trigger its own growth. Following identification of these receptors, the researchers confirmed that by activating them in the laboratory they were able to trigger stem cells growth. Importantly, they also showed that growth could be blocked in a dish and in mice by repurposing drugs against VEGF (Avastin, approved for various solid tumours including colorectal cancer) and IL-5 signalling (Fasenra, approved for eosinophilic asthma).

Professor Olaf Heidenreich from Newcastle University and the Princess Maxima Centre of Pediatric Oncology says:

An exciting result from these studies is the fact that the expression of these receptors is specific to this particular type of leukemia. They are expressed as a result of the presence of a specific disease-causing mutation giving rise to the onco-fusion protein RUNX1::ETO which reprograms the gene regulatory network that defines how a cell responds to outside growth signals.

"This work highlights the power of single cell analysis for digging deep into what regulates the growth of AML cells. It also highlights the fact that AML sub-types may have to be treated as a separate entities.

The first author of the study, Dr Sophie Kellaway who is now continuing this research at the University of Nottingham says:

"We were very excited to find not one but two new, and potentially druggable targets to prevent relapse in these patients. Being told your cancer has come back is devastating news and we want to prevent this happening. Unfortunately, as these receptors were so specific this would only work for t(8;21) acute myeloid leukaemia and is not a magic bullet.

"However, inspection of other single cell data from different leukaemia sub-types show that other growth regulatory pathways are upregulated in their stem cell population as well. We are now hoping to find those that can be hit in other types of AML".

Dr Suzanne Rix, from Blood Cancer UK, said: Blood cancer is the UKs third biggest cancer killer and acute myeloid leukaemia is a particularly aggressive form of blood cancer that can come back even after initial treatments have been successful.

"This research uncovers why one specific type of acute myeloid leukaemia can return, and could lead to the development of new treatments with the potential to stop the cancer coming back, giving new hope to people affected by this specific form of leukaemia. However, further work is needed to see whether a similar approach could be taken for other forms of acute myeloid leukaemia and more broadly much more research is desperately needed to develop effective, kinder treatments for all blood cancers.

See the rest here:
Stopping the awakening of sleeping Acute Myeloid Leukaemia stem cells to prevent disease relapse - University of Birmingham

Unlocking the power of stem cell therapy – Drug Target Review

In this Q&A, founder of Scheer Medical Wellness Dr Alexander Scheer shares his insights, discussing the current challenges in stem cell therapy and how these can be addressed, the advancements in delivery techniques, and stem cells overall potential in regenerative medicine.

Adipose-derived stem cells (ADSCs) have garnered attention due to their remarkable ability to differentiate into various cell types crucial for tissue regeneration and repair. Their plasticity allows them to adapt to the microenvironment of host tissues, facilitating integration and functional restoration. Additionally, ADSCs possess immunomodulatory properties, enabling them to modulate immune responses and promote tissue healing. These characteristics position ADSCs as promising candidates for addressing a wide range of medical conditions, from degenerative diseases to traumatic injuries.

Despite their potential, ADSC therapy faces several challenges in preclinical studies. These include ensuring controlled differentiation of ADSCs into desired cell types, addressing safety concerns such as the risk of tumorigenicity or immunogenicity, and optimising large-scale production methods. To overcome these challenges, researchers employ rigorous preclinical assessments, refine culture techniques to enhance cell purity and functionality, and develop standardised protocols for consistent results.

Researchers commonly use a combination of in vitro cell culture assays and in vivo animal models to assess the therapeutic potential of ADSCs. While in vitro assays provide controlled environments for studying cellular behaviour and differentiation, in vivo models offer insights into tissue-level interactions and responses. However, translating findings from these models to clinical trials requires careful consideration of factors such as disease complexity, species differences, and the relevance of model systems to human physiology.

Recent advancements in delivery techniques have significantly enhanced the precision and effectiveness of ADSC treatments. Biomaterial-based scaffolds provide structural support and mimic the extracellular matrix, facilitating tissue regeneration and integration. Additionally, innovations in 3D bioprinting enable the fabrication of complex tissue structures, offering tailored solutions for patient-specific needs. These delivery techniques improve cell retention, viability, and functionality post-transplantation, maximising therapeutic outcomes.

ADSC therapy holds promise for a multitude of medical conditions, including but not limited to wound healing, organ repair, autoimmune disorders, and cancer treatment. In wound healing, ADSCs accelerate tissue regeneration and reduce scarring, offering hope for chronic wound management. Similarly, in organ repair, ADSCs contribute to tissue regeneration and functional restoration, potentially revolutionising treatments for conditions such as myocardial infarction and liver cirrhosis. Moreover, their immunomodulatory properties make them valuable assets in managing autoimmune diseases by suppressing aberrant immune responses. Furthermore, ongoing research explores the potential of ADSCs in cancer therapy, both in supporting conventional treatments and directly targeting cancer cells. Overall, ADSC therapy represents a versatile and promising approach in personalised and regenerative medicine, with the potential to improve patient outcomes and quality of life across diverse medical fields.

Author bio

Dr Alexander Scheer

Founder of Scheer Medical Wellness

Dr Alexander Scheer, the founder of Scheer Medical Wellness, is a New York-based physician, with more than 20 years of expertise. He serves as the Medical Director (MD) of Scheer Medical Wellness, a cutting edge practice which provides a comprehensive range of high-quality services. These services encompass pain management, neurosurgery, spinal surgery, orthopedic surgery, primary care, physical therapy, physical medicine and rehabilitation, podiatry, plastic surgery, acupuncture, weight loss management, gastroenterology, and sports medicine.

Dr Scheer earned his medical degree from New York Medical College and subsequently completed his Surgical internship at Mount Sinai Beth Israel, followed by training in neurological surgery at the Albert Einstein College of Medicine until 2009. Dr Scheer is licensed to practice medicine in the state of New York and has dedicated his career to enhancing the well-being of his patients, enabling them to lead long and healthy lives.

View original post here:
Unlocking the power of stem cell therapy - Drug Target Review

‘Heart-on-a-Chip’ For Safer Cancer Treatment – Newswise

Newswise LOS ANGELES (Feb. 1, 2024) --Chemotherapy can be toxic to heart cells. To help protect the hearts of cancer patients, Cedars-Sinai investigators have created a three-dimensional heart-on-a-chip to evaluate drug safety. In a study published in the peer-reviewed journalLab on a Chip,they show that the heart-on-a-chip, created using stem cells, accurately predicts the effects of drugs on human heart cells.

The investigators worked with induced pluripotent stem cells, which are blood cells that have been reprogrammed into stem cells and can be turned into any cell type in the body. They used the stem cells to create two types of heart cells, but instead of placing them all together in an unstructured cell culture dish, as is usually done in heart toxicity testing, the investigators introduced the cells into specialized chips.

The 3D chips feature two channels that are arranged to cross each other, keeping each cell type separate but allowing them to interact. The chips also allow for movement and the introduction of fluids.

We grew heart muscle cells and blood vessel cells, saidArun Sharma, PhD, a research scientist in theBoard of Governors Regenerative Medicine Institute,Smidt Heart Institute,Cedars-Sinai Cancer, and theDepartment of Biomedical Sciencesat Cedars-Sinai and senior author of the study. The chip allows us to stretch the cells back and forth to mimic a heartbeat, and to introduce fluid to mimic the flow of blood through the heart. Its like giving the cells a workout that strengthens the muscle cells and allows the vessel cells to form mini blood vessel-like structures.

These matured cells provide a better test platform for drug toxicity studies than cells that havent undergone this maturation process because they more closely resemble the way adult heart cells function, Sharma said.

To demonstrate the proficiency of heart-on-a-chip as a drug-testing platform, the research team, including lead author and postdoctoral fellowMaedeh Mozneb, PhD, subjected the heart chip to a chemotherapy drug called a VEGFR/PDGFR-inhibiting tyrosine kinase inhibitor, which is known to have adverse effects on heart muscle and blood vessel cells. Damage was observed to both cell types in the heart chips.

If future studies continue to show good results, heart-on-a-chip technology could significantly reduce drug development costs and improve the rate at which new therapies become available.

Another future possibility for these heart chips is the creation of patient-specific chips to personalize cancer treatment.

If a patient with cancer might receive a treatment that could have adverse effects on their heart, we can create induced pluripotent stem cells from a small sample of their blood, Sharma said. We can turn those stem cells into heart muscle and blood vessel cells and put them on a chip that will serve as a personalized avatar for how that persons heart might react to the treatment. This is one of the most exciting applications of this technology, truly advancing personalized medicine at Cedars-Sinai.

Also a possibility: Taking these chips beyond a single organ.

We eventually hope to bring our various organ models together, saidClive Svendsen, PhD, executive director of the Board of Governors Regenerative Medicine Institute and co-author of the study. My lab has beenfine-tuning this technologyto help us develop models of neurological diseases, and other labs in our institute have been working on chips for the liver and the gut microbiome. Bringing all of these chips together to create a patient-on-a-chip model is part of our long-term vision for precision medicine.

Funding: This project was supported by American Heart Association Career Development Award 856987; National Institutes of Health grant numbers T32 HL116273, 1UG3TR003148, and 5UG3NS105703; Allen Distinguished Investigator Award number 12879; the Cedars-Sinai Board of Governors Regenerative Medicine Institute; and The ALS Association.

Read More from Discoveries:Regenerative MedicineA New Path for ALS Treatment

See the original post here:
'Heart-on-a-Chip' For Safer Cancer Treatment - Newswise

It’s been a struggle getting out of bed – Liam Harrison on the sheer difficulty of living through injuries before stem cell … – Sportskeeda

Combat sports is often a cruel mistress, and Liam Harrison knows that price all too well.

Behind his world titles, accolades, and overall praise, Harrison also had to deal with the physical toll of achieving such greatness.

In an interview with the South China Morning Post, the British Muay Thai legend discussed how his daily life became a constant struggle after he put his body through immense damage throughout his entire career.

Harrison practically lived on one leg after he suffered a nasty knee injury during his world title fight against Thai legend Nong-O Hama at ONE on Prime Video 1.

Apart from a shattered left knee, Liam Harrison also dealt with the lingering pain that he went through before he challenged for the ONE bantamweight Muay Thai world title in August 2022.

He said:

Things only got better for Harrison when he underwent stem cell treatment in Costa Rica earlier this year, and it was a lofty price to keep his body from breaking down even before he reached 40 years old.

Harrison has since returned to training and is looking forward to what could be his final fight in ONE Championship.

Watch Harrison's entire interview below:

Liam Harrison has no apprehensions about his impending retirement, and he already named the fighter he wants to share the ring with for the final time in his career.

In the same interview, Harrison expressed his desire to take on Seksan Or Kwanmuang for his retirement bout:

See original here:
It's been a struggle getting out of bed - Liam Harrison on the sheer difficulty of living through injuries before stem cell ... - Sportskeeda

Houston regenerative medicine company to IPO, move toward more human trials – InnovationMap

Want a piece of one of Houstons most promising biotech companies? On January 31, FibroBiologics will begin the trading of its common stock on the Nasdaq stock exchange.

While most labs in the realm of regenerative medicine are focused on stem cells, FibroBiologics has bet on fibroblasts as the secret to treating myriad ailments. Fibroblasts, the most common type of cell in the body, are the primary cells that compose connective tissue.

Interested investors can find a prospectus to peruse before taking the leap. FibroBiologics filed with the U.S. Securities & Exchange Commission (SEC) on November 7, 2023. In September, FibroBiologics CEO Pete OHeeron told InnovationMap, I think what we're going to see is that fibroblasts are going to end up winning... They're just a better overall cell than the stem cells.

OHeeron was first exposed to the possibilities of fibroblasts as a means of regrowing discs in the spine. Since starting the company in 2008 as SpinalCyte, OHeeron and FibroBiologics have organically written and filed more than 320 patents. Potential treatments go far beyond spinal surgery to include wound care, cancer, and multiple sclerosis.

According to OHeeron, the goal in going public is to raise capital for human trials.

Weve had really fantastic results with animals and now were ready for humans, he explained in September. We've done small human trials, but we haven't done the large ones that are going to get the commercialization approval from the FDA.

FibroBiologics is growing with impressive speed. OHeeron told us that he is hiring as quickly as he is able to find qualified scientists with the expertise to do the one-of-a-kind work required. The company opened a new lab last fall at the UH Technology Bridge, Newlin-Linscomb Lab for Cell Therapies. With its new status as a publicly traded company, FibroBiologics is primed to break even more ground.

See the article here:
Houston regenerative medicine company to IPO, move toward more human trials - InnovationMap

Rebirth Clinics Launches State-of-the-Art Stem Cell Centers in Abu Dhabi and Dubai – PR Web

Leading Regenerative Medicine, Rebirth Clinics Brings Innovative Stem Cell and Anti-Aging Therapies to the UAE

HONG KONG, Feb. 1, 2024 /PRNewswire-PRWeb/ -- Rebirth Clinics, a global leader in regenerative medicine products and services, today announced the launch of two of its "Rebirth Clinics" in Abu Dhabi and Dubai. The launch enables them to meet increasing market demand for stem cell treatments and Anti-Aging Therapies.

In addition to offering the highest-grade stem cell therapies available on the marketFour days old xeno-free stem cells sourced from fresh umbilical cord tissueRebirth Clinics also provide regenerative therapies including NAD+, Brain Peptides, Multi-Vitamins, and more.

"We are living in a historic time, where we are witnessing the emergence of stem cell therapy as a rapidly growing modality that will soon become a standard of care in modern medicine," said Ronny Shany, Founder of Rebirth Clinics, "Science has given us an amazing gift with stem cells; they are providing us with answers to medical challenges that have remained beyond our grasp for too long. At Rebirth, we fully embrace this gift, as there are so many diseases that can now be cured, and so many people suffering who can now be helped, it's good business and it's good medicine."

"We are thrilled to announce the expansion of Rebirth Clinics into Abu Dhabi," said Dr. Nashwa Al Ruwaini, CEO of Pyramedia Group, "This venture not only aligns with our commitment to healthcare innovation but also marks a significant step in making advanced regenerative medicine accessible in the region. Our collaboration with Rebirth Clinics LTD. is a testament to our dedication to bringing the latest in stem cell therapies and anti-aging treatments to our community. We envision a future where cutting-edge treatments like umbilical cord stem cell therapies become a cornerstone in modern healthcare. However, it's important to acknowledge that these forward-looking statements are based on current market trends and scientific advancements, and as the medical landscape evolves, so too may our strategies. We are committed to adapting and growing in this dynamic field".

"We are proud to be at the forefront of introducing revolutionary stem cell therapies to our patients", added Dr. Mohamed Al Ruwaini, Director of Delma Medical Center, "This collaboration with Rebirth Clinics in Abu Dhabi signifies a major leap in our mission to offer the most advanced medical treatments available. By integrating Rebirth Clinics' expertise in stem cell therapy, including their groundbreaking umbilical cord stem cell treatments, we are set to redefine healthcare standards in the region. Our commitment to excellence remains steadfast, even as we adapt to new developments and challenges in this pioneering area of healthcare".

Rebirth Clinics is a groundbreaking medical institute dedicated to transforming the landscape of advanced medical rejuvenation therapies using fresh Umbilical cord stem cells and IV treatments. As a leader in the regenerative medicine and the cellular therapy industry, Rebirth specializes in physician training certification, stem cell products, and IV therapies, with its lead product, fresh Umbilical cord stem cells. In addition, the organization is involved with the creation and management of stem cell clinics around the world.

"The opportunity to be a part of history at a time when we are witnessing an incredible paradigm shift in the use of stem cell therapy is monumental," said Derek Halpern, Chief Marketing Officer of Rebirth Clinics. "All advancements in science require time. By diversifying our regenerative medicine offerings, we are moving through this very important time in medicine while simultaneously making sure our customers continue to have a variety of safe and effective options for their care that will empower them to choose the product and/or service they feel is right for them."

For more information about Rebirth Cinics, visit their website at http://www.Rebirthglobe.com.

Media Contact

Derek Halpern, CMO, Rebirth Clinics, +1-5162346564, derek@svnetworx.com,http://Www.Rebirthglobe.com

SOURCE Rebirth Clinics

See the original post here:
Rebirth Clinics Launches State-of-the-Art Stem Cell Centers in Abu Dhabi and Dubai - PR Web